Allergan bets on rising popularity of botox for men
Move is part of firm's strategy to go after smaller markets in traditional pharmaceutical industry
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
New York
FINE lines. Double chins. Sagging skin. Allergan Plc is betting that these byproducts of ageing are becoming an obsession for men.
After completing a deal valued at US$70.5 billion to buy the maker of Botox injections, Allergan announced on Wednesday that it would pay US$2.1 billion for Kythera Biopharmaceuticals Inc. The latest transaction gives the company an experimental drug for male-pattern baldness and an injection that is the only regulator-approved non-surgical treatment for a double chin - a condition that Kythera has said bothers men as much as women.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
OCBC is said to emerge as lead bidder for HSBC Indonesia assets
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
